pp-147 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Metastatic colorectal cancer (RAS-mutant; 2L after FOLFOX failure)
Clinical stage: Phase 2b
Modality: Small molecule
Mechanism / Target: Creatine transporter (SLC6A8) inhibitor — blocks creatine uptake in RAS-mutant tumour cells that depend on creatine for energy; causes metabolic vulnerability-driven apoptosis
Route / form: Oral tablet
Differentiation: First-in-class metabolic target in CRC; RAS-mutation selectivity creates a defined patient population; addresses unmet need in largest unresponsive CRC subset
Manufacturer #39178
Clinical-stage oncology company targeting cancer metabolic vulnerabilities. Focuses on nutrient transport inhibition as a novel strategy in RAS-driven colorectal cancer. Wholly owned first-in-class creatine transporter inhibitor advancing in Phase 2.
None